|Videos|December 18, 2017

Predicting Unplanned Hospital Readmissions in Patients With Hematologic Malignancies

This video highlights results of a study that examined predictors for unplanned hospital readmissions in patients with hematologic malignancies.

In this video, Sudipto Mukherjee, MD, MPH, of the Cleveland Clinic in Ohio, discusses results of a study that examined predictors for unplanned hospital readmissions in patients with hematologic malignancies.

Results of the study (abstract 532) were presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Predicting Unplanned Hospital Readmissions in Patients With Hematologic Malignancies

Related Content

Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL

Pirtobrutinib Combo Boosts PFS in Previously Treated CLL/SLL

TA-TMA and GVHD Are Distinct Consequences of Endothelial Injury: A MIDAS Consortium Study

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

Equitable Access to Cellular Therapy Requires More Than Certification

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Kansas Society of Clinical Oncology

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

25th Annual International Congress on the Future of Breast Cancer® East

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

25th Annual International Congress on the Future of Breast Cancer® West

Arizona Clinical Oncology Society

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Wisconsin Association of Hematology and Oncology

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Colorado Oncology Society

27th Annual International Lung Cancer Congress®

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Satellite Symposia at the Annual Radiation Oncology Meeting

Empire State Hematology & Oncology Society (New York)

Minnesota Society of Clinical Oncology

North Carolina Oncology Association

Louisiana Oncology Society

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Trending on CancerNetwork

Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma

Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer

GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma